Ranbaxy Foils Mylan's Challenge To Valsartan Exclusivity

Law360, Washington (January 2, 2013, 3:28 PM EST) -- A Washington federal judge on Thursday tossed Mylan Pharmaceuticals Inc.'s suit against the U.S. Food and Drug Administration that attempted to gain marketing approval for its generic hypertension drug valsartan, saying Ranbaxy Laboratories Ltd.'s first-to-file exclusivity for the generic remains intact.

Although Ranbaxy received its tentative FDA approval for its generic version of valsartan nearly four months after the deadline, U.S. District Judge John D. Bates determined the delay was understandable, as the approval requirements changed within the 30-month period in which Ranbaxy had to obtain...
To view the full article, register now.